文献速递治疗药物监测与药物基因组学特殊人群用药

CES1基因变异对依那普利稳态药代动力学和药效学的影响

Effect of CES1 genetic variation on enalapril steady-state pharmacokinetics and pharmacodynamics in healthy subjects.
PubMed 文献 · Br J Clin Pharmacol · 2021-05-26

本研究纳入健康志愿者,按CES1 G143E变异分层为非携带者(n=15)和携带者(n=6),所有携带者均为杂合子。受试者连续7天每日服用依那普利10 mg后进行72小时PK/PD研究。结果显示,携带者依那普利活性代谢物依那普利拉的Cmax降低30.9%(P=0.03)、AUC0-∞降低27.5%(P=0.02),依那普利拉/依那普利AUC0-∞比值降低32.3%(P=0.003);非携带者研究结束时收缩压较基线平均降低约12.4%(P=0.001),而携带者未观察到统计学显著的血压下降。结论认为CES1功能缺失型G143E变异显著损害依那普利的活化及其收缩压降低效应。

要点

  • CES1 G143E携带者依那普利拉Cmax降低30.9%、AUC0-∞降低27.5%。
  • 携带者依那普利拉/依那普利AUC0-∞比值降低32.3%。
  • 非携带者收缩压平均降低约12.4%,携带者无显著血压下降。

核心结论

  • CES1功能缺失型G143E变异显著损害依那普利的活化及其收缩压降低效应。

研究设计与样本

  • 前瞻性、多剂量药代动力学/药效学研究,健康志愿者按CES1 G143E分层为非携带者(n=15)和携带者(n=6),携带者均为杂合子。
  • 受试者连续7天每日服用依那普利10 mg,随后进行72小时PK/PD研究。
  • 采用液相色谱-串联质谱法(LC-MS/MS)测定依那普利及其活性代谢物依那普利拉的血浆浓度。

主要发现

  • 携带者依那普利拉Cmax为38.01 ng/mL,非携带者为55.01 ng/mL,携带者降低30.9%(P=0.03)。
  • 携带者依那普利拉AUC0-∞为374.29 ng*h/mL,非携带者为515.91 ng*h/mL,携带者降低27.5%(P=0.02)。
  • 携带者依那普利拉/依那普利AUC0-∞比值较非携带者降低32.3%(P=0.003)。
  • 非携带者研究结束时收缩压较基线平均降低约12.4%(P=0.001),携带者未观察到统计学显著的血压下降。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Enalapril is a prodrug and needs to be activated by carboxylesterase 1 (CES1). A previous in vitro study demonstrated the CES1 genetic variant, G143E (rs71647871), significantly impaired enalapril activation. Two previous clinical studies examined the impact of G143E on single-dose enalapril PK (10 mg); however, the results were inconclusive. A prospective, multi-dose, pharmacokinetics and pharmacodynamics (PK/PD) study was conducted to determine the impact of the CES1 G143E variant on enalapril steady-state PK and PD in healthy volunteers. METHODS: Study participants were stratified to G143E non-carriers (n = 15) and G143E carriers (n = 6). All the carriers were G143E heterozygotes. Study subjects received enalapril 10 mg daily for seven consecutive days prior to a 72 hour PK/PD study. Plasma concentrations of enalapril and its active metabolite enalaprilat were quantified by an established liquid chromatography-tandem mass spectrometry (LC-MS/MS) method. RESULTS: The CES1 G143E carriers had 30.9% lower enalaprilat Cmax (P = 0.03) compared to the non-carriers (38.01 vs. 55.01 ng/mL). The carrier group had 27.5% lower AUC0-∞ (P = 0.02) of plasma enalaprilat compared to the non-carriers (374.29 vs. 515.91 ng*h/mL). The carriers also had a 32.3% lower enalaprilat-to-enalapril AUC0-∞ ratio (P = 0.003) relative to the non-carriers. The average maximum reduction of systolic blood pressure in the non-carrier group was approximately 12.4% at the end of the study compared to the baseline (P = 0.001). No statistically significant blood pressure reduction was observed in the G143E carriers. CONCLUSIONS: The CES1 loss-of-function G143E variant significantly impaired enalapril activation and its systolic blood pressure-lowering effect in healthy volunteers.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Her LH, Wang X, Shi J, et al. Effect of CES1 genetic variation on enalapril steady-state pharmacokinetics and pharmacodynamics in healthy subjects. Br J Clin Pharmacol. 2021. PMID: 33963573. doi:10.1111/bcp.14888

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。